The Second Bite: How Rollover Equity Works and Who Gets Paid First

A $5,000,000 practice sale closed. Here is what the seller actually received on closing day:

$2,750,000 in cash. $750,000 in escrow for three years, chargeable against “pre-existing conditions.” And $1,500,000 in stock of the buyer’s platform — a company the seller had never audited.

Component	Amount	Share of headline	What it actually is
Cash at close	$2,750,000	55%	Money
Escrow holdback	$750,000	15%	Money the buyer can charge against for 36 months
Rollover equity	$1,500,000	30%	A minority security in an unaudited company
Headline price	$5,000,000	100%

Source: Precision Dental Analytics; structure consistent with typical institutional dental deals (cash at close 40–60%, escrow 15–20%, rollover 20–40%).

That stock has a nickname the industry loves: the second bite of the apple. Sell once at 7×, roll a piece into the platform, and when the sponsor recapitalizes in five years at a higher multiple, sell again. Sometimes it is the best money in the deal. It is a security, however: minority, illiquid, usually leveraged, with an exit you do not control. And as a rule, securities get diligenced.

Last week I wrote that the earnout is contingent payment. Rollover equity is contingent ownership. The same rule applies: the number on the term sheet is not the number you will receive. The value realized is contingent on definitions.

The Asymmetry Nobody Names

Before that $5M deal closed, the buyer spent 90 days inside the practice. A Quality of Earnings team pulled five years of PMS data, stress-tested every add-back, benchmarked every code. The buy-side diligence investment for this deal likely ran $50,000–$70,000.

Now be generous to the seller, because he deserves it. He was curious. He asked how many locations the platform had and where it was headed. He asked who the sponsor was and when the recap was planned. He read the slide deck and everything he could, twice. He called two doctors who had sold into the platform the year before, and both were happy. He had his attorney review the operating agreement for the deal points.

That is a conscientious person doing everything a conscientious person knows to do. And it does not measure the same thing.

The buyer measured the asset: procedure-level data against payer and operational benchmarks, every add-back against third-party documentation, every number against what the practice would look like the day the seller left. The seller measured a narrative: growth, momentum, a sponsor’s reputation, two satisfied peers. Every piece of it may have been true the moment he heard it. None of it was a claim on the platform’s balance sheet, its cap table, its debt, or its distribution waterfall. He learned what the company said about itself. The buyer learned what the practice’s data said regardless of what the seller believed about it.

And those two happy doctors? They sold early — insulated by early valuations, ahead of the dilution from every acquisition that followed. Which is exactly why they were happy, and exactly why their experience predicts nothing about the tenth seller’s. A reference check is not a capital structure.

So the party with less experience did less diligence — not less effort, less measurement — on the more complicated instrument. That is the second bite’s original sin, and everything below follows from it.

What You Actually Hold: Five Questions

Rollover equity typically runs 20–40% of total consideration. Here is what determines whether yours is a second bite or a second haircut.

1. Which class? Are your units the same class the sponsor holds, or a common class sitting beneath a preferred class? Preferred equity carries a preferred return and a liquidation preference: at any exit, it gets paid first, with its accrued return, before common sees a dollar. If the platform sells for less than the preferred stack, common equity — the seller in this example — receives nothing, and the sponsor still gets paid.

2. Where in the waterfall? Even inside the same class, the distribution order at exit is written in the operating agreement. Sponsor fees, accrued preferred returns, debt repayment, management incentive pools — each takes a slice before the residual reaches you. Ask for the waterfall. If the answer is a diagram instead of a document, that is your answer.

3. What dilutes you? Every subsequent acquisition the platform makes issues new units. Every capital raise issues more. Every management incentive pool carves out a share. Your percentage shrinks with each one. Without anti-dilution protection or preemptive rights, you’ve agreed to have no say and no defense. The first sellers into a platform are insulated by early valuations. The tenth seller is holding a percentage that has been diluted by the eleventh through the fortieth.

4. What can you see? Do you have contractual information rights — audited financials, quarterly reporting, an annual valuation? Without them, you own a percentage of something you cannot inspect, and you find out what happened to it after it has happened.

5. How do you get out? There is no market for platform units. You cannot sell them when you want to. Your only path to cash is the recapitalization — the day the sponsor sells the platform to the next buyer and everyone’s paper converts to money. That day may come in five years, in eight, or not at all, and the valuation on that day is set by a transaction you have no seat at. Until then, the $1.5M is a number on a statement.

The Public Record

In July 2023, more than 100 dentists filed suit against ZAHN Parent, LLC, an affiliate of North American Dental Group, which Jacobs Holding had acquired in 2019. The dentists had sold their practices in exchange for membership units. According to industry reporting, they sought financial reports, tax returns, and valuation documents after an event that allegedly reduced the valuation of their units and significantly diluted their ownership.

Notice what the lawsuit was: a fight to see the documents. Over a hundred practice owners held equity and had to litigate to learn what had happened to it. That is question four proving its own necessity, in a courtroom.

I have no inside knowledge of that matter and make no claim about its merits. I cite it because it is the public, verifiable version of a story that owners tell each other constantly in private. In a recent thread of dentists comparing notes on their DSO exits, the pattern was unmistakable: the sellers still happy years later had taken 75% in cash and treated the equity as “icing on the cake if and when that money comes.” The sellers with regrets had believed the second bite was the plan rather than the option.

The Math of the Pitch

The second-bite pitch is a clean multiplication: $1.5M rolled, platform recaps in five years at 2–3× the entry valuation, your stake is worth $3–4.5M. The arithmetic is not wrong. It just assumes five things at once: that the recap happens, on schedule, at that multiple, with your percentage undiluted, and with your class paid alongside the sponsor’s.

Every one of those assumptions is a clause. None of them is a default.

The Seller-Structured Version

What good looks like, in the operating agreement rather than the pitch deck: the same class of units the sponsor holds — or, if the structure won’t allow that, language that puts you pari passu with them at exit, which is the contractual way of saying: when the money comes out, your dollar and the sponsor’s dollar get paid at the same time, at the same rate, from the same pool. Nobody ahead of you in line. Without it, “equity” can mean you own a percentage of whatever is left after everyone who wrote the agreement has been paid.

Then the rest of the package: preemptive rights or anti-dilution protection, with a cap on how much the management incentive pool can carve out. Information rights — quarterly financials, annual audited statements, an annual valuation — so you never have to sue to see what you own. Tag-along rights, so the sponsor cannot exit and leave you behind. A defined liquidity path — a put right or a hard date — if the recap hasn’t happened within a stated window. And any redemption valued by a methodology written in the document, not “as determined by the board.”

None of that is as exotic as it sounds. It is the standard package a sponsor’s own investors receive. You are asking to be treated like the capital you are.

Where the Leverage Comes From

The same place it always does. A seller holding a defensible, audited number and a practice that demonstrably runs without them is negotiating from strength, which shows up first as less contingent consideration. More cash at close. A smaller rollover, by choice rather than by structure. Whatever equity remains, held on terms you can inspect.

You don’t negotiate your way to a good second bite. You audit your way to a smaller one — and then diligence the apple before you take it.

The Bottom Line

The first bite is a payment. The second bite is a bet — on a company you didn’t build, run by people who audited you far more carefully than you audited them.

Securities get diligenced. Diligence improves the odds of your bet.